Want to join the conversation?
Jamie Baker of JP Morgan asks about the decline in other revenue. $DAL said one of the drivers of the decline was lower YoverY third-party sales from the refinery. With the lower crude oil prices, the product values were substantially down and this formed $65MM of the decline.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.